Compare BioNano Genomics Inc (BNGO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Jones Lang LaSalle Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Jones Lang LaSalle Inc trades at $362.82 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is far larger — about 1224× BioNano Genomics Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | JLL | |
|---|---|---|
Market Cap | $13.66M | $16.72B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $373.24 |
52-Week Low | $1.06 | $280.16 |
Enterprise Value | $16.26M | $19.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
JLL trades at $362.81, up 1.53% today, near its 52-week high. The stock exhibits strong technical momentum with a bullish moving average crossover and is supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue growth accelerated to $26.12 billion in 2025, with net income margin improving to 3.64%. Analyst sentiment is positive with a 54.55% buy rating and a consensus price target of $391.50, suggesting further upside potential from current levels.
The outlook for JLL is favorable, driven by robust earnings performance and solid cash flow generation. Key opportunities include continued growth in leasing and capital markets, while risks involve economic sensitivity and competitive pressures in real estate services. The stock's valuation at a P/E of 17.43 and P/S of 0.63 appears reasonable relative to growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
